KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBT: 2018-2024

Historic EBT for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $21.6 million.

  • Castle Biosciences' EBT fell 104.66% to -$386,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.9 million, marking a year-over-year decrease of 269.82%. This contributed to the annual value of $21.6 million for FY2024, which is 137.59% up from last year.
  • Per Castle Biosciences' latest filing, its EBT stood at $21.6 million for FY2024, which was up 137.59% from -$57.4 million recorded in FY2023.
  • Castle Biosciences' EBT's 5-year high stood at $21.6 million during FY2024, with a 5-year trough of -$68.9 million in FY2022.
  • Its 3-year average for EBT is -$34.9 million, with a median of -$57.4 million in 2023.
  • As far as peak fluctuations go, Castle Biosciences' EBT plummeted by 292.27% in 2021, and later soared by 137.59% in 2024.
  • Yearly analysis of 5 years shows Castle Biosciences' EBT stood at -$10.2 million in 2020, then tumbled by 292.27% to -$40.0 million in 2021, then plummeted by 72.21% to -$68.9 million in 2022, then increased by 16.75% to -$57.4 million in 2023, then skyrocketed by 137.59% to $21.6 million in 2024.